Most of the early gene therapy trials for cystic fibrosis have been with adenovirus vectors.
First-generation viruses with E1a and E1b deleted are limited by transient expression of the …

Pre-existing immunity to human adenovirus serotype 5 (Ad5) is common in the general
population. Bypassing pre-existing immunity could maximize Ad5 vaccine efficacy. Vaccination …

One disadvantage of vesicular stomatitis virus G (VSV-G) pseudotyped lentivirus vectors for
clinical application is inactivation of the vector by human serum complement. To prevent this, …

Systemic administration of adenoviral vectors leads to activation of innate and antigen-specific
immunity. In an attempt to diminish T and B cell-specific immune responses to E1-deleted …

Ebola is a highly virulent pathogen causing severe hemorrhagic fever with a high case fatality
rate in humans and non-human primates (NHPs). Although safe and effective vaccines or …

PEGylation is the covalent attachment of activated monomethoxy poly(ethylene) glycols (MPEGs)
to free lysine groups of therapeutic proteins. This technology has enhanced the …

Background The Ebola virus is transmitted by direct contact with bodily fluids of infected
individuals, eliciting death rates as high as 90% among infected humans. Currently, replication …

A novel, thin-film platform that preserves live viruses, bacteria, antibodies, and enzymes
without refrigeration for extended periods of time is described. Studies with recombinant …

Marburg and Ebola hemorrhagic fevers have been described as the most virulent viral
diseases known to man due to associative lethality rates of up to 90%. Death can occur within …

Adeno-associated virus (AAV), capable of producing significant, long-term transgene
expression, is one of the least toxic vectors employed in pre-clinical and clinical studies of gene …